PROVASOPRESSIN ANTAGONISTS AND USES THEREOF

    公开(公告)号:CA2854563A1

    公开(公告)日:2013-05-16

    申请号:CA2854563

    申请日:2012-11-09

    Abstract: Provided herein are pro- VP antagonists, such as antibodies and antigen-binding portions thereof specific for pro- VP, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples. The compositions may also be used for treating patients suffering from a provasopressin-expressing cancer. Provasopressin- expressing cancers include neuroendocrine cancer, pancreatic cancer, and prostate cancer.

    Antagonists for abnormal vasopressin V2 receptor and uses thereof

    公开(公告)号:AU2012335618A1

    公开(公告)日:2014-06-12

    申请号:AU2012335618

    申请日:2012-11-09

    Abstract: Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V2 (e.g., AbnV2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor V2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro. The antagonists or binding agents may also be used for treating patients suffering from a cancer expressing the abnormal vasopressin receptor V2, such as small cell lung cancer (SCLC), breast cancer, or ovarian cancer.

    ANTAGONISTS FOR ABNORMAL VASOPRESSIN V2 RECEPTOR AND USES THEREOF

    公开(公告)号:CA2854467A1

    公开(公告)日:2013-05-16

    申请号:CA2854467

    申请日:2012-11-09

    Abstract: Provided herein are antagonists or binding agents of an abnormal vasopressin receptor V2 (e.g., AbnV2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor V2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro. The antagonists or binding agents may also be used for treating patients suffering from a cancer expressing the abnormal vasopressin receptor V2, such as small cell lung cancer (SCLC), breast cancer, or ovarian cancer.

Patent Agency Ranking